melatonin has been researched along with Cancer of Prostate in 87 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, the effects of melatonin or beta-glucan treatments on tumor growth, pro-oxidant, and antioxidant status in tumor tissue were investigated in Dunning 3327 MatLyLu prostatic adenocarcinoma model." | 7.77 | Melatonin and beta-glucan alone or in combination inhibit the growth of dunning prostatic adenocarcinoma. ( Balkan, J; Doğru-Abbasoğlu, S; Kabasakal, L; Keyer-Uysal, M; Sener, G; Uysal, M, 2011) |
| "The effects of the pineal indole melatonin on a transplantable androgen-insensitive fast-growing rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor, were examined." | 7.67 | Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor. ( Buzzell, GR, 1988) |
| "To test this hypothesis, LNCaP human prostate cancer cells were xenografted into seven-wk-old Foxn1nu/nu male mice that were treated with melatonin (18 i." | 5.40 | Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. ( Bianciardi, P; Bonomini, F; Favero, G; Finati, E; Fraschini, F; Paroni, R; Reiter, RJ; Rezzani, R; Samaja, M; Terraneo, L; Virgili, E, 2014) |
| "Conventional antiandrogen therapy for prostatic cancer generally results in the death of androgen-dependent cells, resulting in shrinkage of the tumor, followed by regrowth of the tumor as androgen-insensitive cells take over." | 5.27 | Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma. ( Amerongen, HM; Buzzell, GR; Hennes, SC; McBlain, WA; O'Brien, MG; Toma, JG, 1987) |
| "In this study, the effects of melatonin or beta-glucan treatments on tumor growth, pro-oxidant, and antioxidant status in tumor tissue were investigated in Dunning 3327 MatLyLu prostatic adenocarcinoma model." | 3.77 | Melatonin and beta-glucan alone or in combination inhibit the growth of dunning prostatic adenocarcinoma. ( Balkan, J; Doğru-Abbasoğlu, S; Kabasakal, L; Keyer-Uysal, M; Sener, G; Uysal, M, 2011) |
| "The melatonin hypothesis states that excess exposure to environmental light may contribute to breast cancer risks via impaired pineal secretion of melatonin." | 3.70 | Does winter darkness in the Artic protect against cancer? The melatonin hypothesis revisited. ( Erren, TC; Piekarski, C, 1999) |
| "The effects of the pineal indole melatonin on a transplantable androgen-insensitive fast-growing rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor, were examined." | 3.67 | Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor. ( Buzzell, GR, 1988) |
| "Injections of the pineal hormone melatonin reduced growth and increased doubling time of the R3327H Dunning prostatic adenocarcinoma in the Copenhagen X Fisher rat." | 3.67 | Inhibition of Dunning tumor growth by melatonin. ( Berkowitz, AS; Philo, R, 1988) |
| "The serum levels of the pineal hormone melatonin were determined by radioimmunoassay (RIA) in 4-h intervals throughout a 24-h period in elderly men with different types of prostate tumors: benign prostatic hyperplasia (BPH, n = 13), incidental carcinoma (PCi, n = 5), and nonmetastasizing carcinoma (PC, n = 9), as well as in young men (YM, n = 10)." | 3.67 | Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. ( Attanasio, A; Bartsch, C; Bartsch, H; Flüchter, SH; Gupta, D, 1985) |
| "Melatonin has therapeutic importance." | 2.72 | The Potential Oncostatic Effects of Melatonin against Prostate Cancer. ( Samanta, S, 2021) |
| "Melatonin is an indole-like neurohormone mainly produced in the human pineal gland with a prominent anti-oxidant property." | 2.72 | The inhibitory effect of melatonin on human prostate cancer. ( Ju, L; Liu, T; Ma, H; Qian, K; Shen, D; Wang, X; Xiao, Y; Yu, M; Zhang, Y; Zhou, F, 2021) |
| "Fifty-nine patients with breast cancer and 10 with prostate cancer enrolled in an eight-week Mindfulness-Based Stress Reduction (MBSR) program that incorporated relaxation, meditation, gentle yoga, and daily home practice." | 2.71 | Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. ( Carlson, LE; Goodey, E; Patel, KD; Speca, M, 2004) |
| "For local Prostate Cancer group, an OR was achieved in 87." | 2.49 | The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature. ( Colori, B; Di Bella, G; Mascia, F, 2013) |
| "Prostate cancer is one of the most commonly diagnosed cancers in Western men and one in three Australian men develops the cancer before the age of 75." | 2.46 | Could mining be protective against prostate cancer? A study and literature review. ( Ambrosini, GL; Fritschi, L; Girschik, J; Glass, D, 2010) |
| "The rational use of melatonin in prostate cancer prevention, stabilization of clinically localized favourable-risk prostate cancer and palliative treatment of advanced or metastatic tumour is discussed within the context of the molecular pathogenesis of the disease." | 2.44 | Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. ( Shiu, SY, 2007) |
| "Melatonin, in turn, has been shown to suppress mammary tumorigenesis in experimental animals." | 2.38 | Electric power, pineal function, and the risk of breast cancer. ( Anderson, LE; Davis, S; Stevens, RG; Thomas, DB; Wilson, BW, 1992) |
| "Melatonin has shown antiproliferative and antimetastatic activities but has not yet been shown to be active in osteoblastic bone lesions of prostate cancer." | 1.72 | Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α ( Guo, JH; Lai, YW; Lin, LW; Lin, TH; Liu, CL; Liu, SC; Swain, S; Tai, HC; Tang, CH; Tsai, HC; Wang, SW; Wu, HC; Yang, SF, 2022) |
| "Melatonin levels were always lower in PCa cases than in controls." | 1.72 | Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study. ( Acuña-Castroviejo, D; Arana-Asensio, E; Fernández-Martínez, J; Jiménez-Moleón, JJ; Jiménez-Pacheco, A; Lozano-Lorca, M; Olmedo-Requena, R; Redondo-Sánchez, D; Rodríguez-Barranco, M; Sánchez, MJ; Vázquez-Alonso, F, 2022) |
| "Melatonin has shown anticancer activity in experimental investigations." | 1.62 | Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression. ( Chang, AC; Chen, PC; Chen, SS; Chen, YH; Lai, YW; Lin, LW; Lin, TH; Tai, HC; Tang, CH; Wang, PC; Wang, SW, 2021) |
| "The association between diabetes and prostate cancer is controversial." | 1.48 | Pathological lesions and global DNA methylation in rat prostate under streptozotocin-induced diabetes and melatonin supplementation. ( de Campos, SGP; Gobbo, MG; Góes, RM; Ribeiro, DL; Taboga, SR; Tamarindo, GH, 2018) |
| "Melatonin has been indicated as a possible oncostatic agent in different types of cancer, its antiproliferative role being demonstrated in several in vitro and in vivo experimental models of tumors." | 1.48 | Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells. ( Bevilacqua, A; Calastretti, A; Canti, G; Dugnani, S; Gatti, G; Lucini, V; Scaglione, F, 2018) |
| "The growth of androgen-sensitive LNCaP prostate cancer cells in mice is inhibited by 3 mg/kg/week melatonin (0." | 1.46 | Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer. ( Bianciardi, P; Finati, E; Paroni, R; Samaja, M; Terraneo, L; Virgili, E, 2017) |
| "Interestingly, the incidence of prostate cancer was significantly associated with ALAN (risk ratio = 1." | 1.46 | The association between artificial light at night and prostate cancer in Gwangju City and South Jeolla Province of South Korea. ( Kim, J; Kim, KY; Kim, YJ; Lee, E, 2017) |
| "Treatment of prostate cancer (PCa), a leading cause of cancer among males, lacks successful strategies especially in advanced, hormone-refractory stages." | 1.46 | IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. ( Cepas, V; Gonzalez-Menendez, P; Gonzalez-Pola, I; Hevia, D; Mayo, JC; Quiros-Gonzalez, I; Rodriguez-Garcia, A; Sainz, RM, 2017) |
| "Few modifiable risk factors for prostate cancer are known." | 1.42 | Residential Exposure to Road and Railway Noise and Risk of Prostate Cancer: A Prospective Cohort Study. ( Eriksen, KT; Hjortebjerg, D; Jensen, SS; Overvad, K; Raaschou-Nielsen, O; Roswall, N; Sørensen, M; Tjønneland, A, 2015) |
| "Melatonin is a derivative of the amino acid tryptophan and reportedly easily crosses biological membranes due to its amphipathic nature." | 1.42 | Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. ( González-Menéndez, P; Hevia, D; Mayo, JC; Miar, A; Quiros-González, I; Reiter, RJ; Rodríguez-García, A; Sainz, RM; Tan, DX, 2015) |
| "Melatonin has anticarcinogenic properties in experimental models." | 1.42 | Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. ( Aspelund, T; Batista, JL; Czeisler, CA; Fall, K; Flynn-Evans, E; Gudnason, V; Haneuse, S; Harris, T; Launer, L; Lockley, SW; Markt, SC; Mucci, LA; Rider, JR; Schernhammer, ES; Sigurdardottir, LG; Stampfer, MJ; Tamimi, RM; Valdimarsdottir, UA, 2015) |
| "To test this hypothesis, LNCaP human prostate cancer cells were xenografted into seven-wk-old Foxn1nu/nu male mice that were treated with melatonin (18 i." | 1.40 | Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. ( Bianciardi, P; Bonomini, F; Favero, G; Finati, E; Fraschini, F; Paroni, R; Reiter, RJ; Rezzani, R; Samaja, M; Terraneo, L; Virgili, E, 2014) |
| "Melatonin has antiproliferative properties in prostate cancer cells." | 1.39 | Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. ( Hevia, D; Mayo, JC; Navarro, M; Quiros-Gonzalez, I; Rodriguez-Garcia, A; Sainz, RM, 2013) |
| "Sphingosine kinase 1 (SPHK1) is a newly discovered modulator of hypoxia inducible factor 1α (HIF-1α) with various biological activities such as cell growth, survival, invasion, angiogenesis, and carcinogenesis." | 1.37 | Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells. ( Chen, CY; Cho, SY; Jeong, SJ; Kim, HS; Kim, SH; Lee, EO; Lee, HJ, 2011) |
| "Substrates were LNCaP and PC-3 prostate cancer cell lines." | 1.36 | The vitamin C:vitamin K3 system - enhancers and inhibitors of the anticancer effect. ( Brignall, MS; Brinton, CA; Gu, YH; Lamson, DW; Plaza, SM; Sadlon, AE, 2010) |
| "Melatonin levels have been shown to decrease in patients with cancer and exogenous melatonin exhibits antiproliferative effects against certain cancers." | 1.36 | Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. ( Ahmad, N; Huang, W; Jung-Hynes, B; Reiter, RJ, 2010) |
| "Melatonin treatment significantly inhibited the growth of LNCaP cells in a dose- and time-dependent manner." | 1.35 | Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. ( Joo, SS; Yoo, YM, 2009) |
| "By using a cellular model of human prostate cancer, we studied the ability of melatonin to enhance apoptosis induced by tumor necrosis factor or gamma radiation." | 1.35 | Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. ( Hevia, D; Mayo, JC; Natarajan, M; Quiros, I; Reiter, RJ; Rodriguez, C; Roldan, F; Sainz, RM; Tan, DX, 2008) |
| "The treatment of prostate cancer cells with pharmacological concentrations of melatonin influences not only androgen-sensitive but also androgen-insensitive epithelial prostate cancer cells." | 1.33 | Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. ( León, J; Manchester, L; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 2005) |
| "Melatonin treatment induced membrane association of PKCalpha in a time and dose dependent manner." | 1.33 | Role of protein kinase Calpha in melatonin signal transduction. ( Braiman, L; Lupowitz, Z; Sampson, SR; Zisapel, N, 2006) |
| "Melatonin treatment was associated with further decreases in LNCaP tumor incidence and growth rate in castrated nude mice." | 1.31 | Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. ( Lau, KW; Shiu, SY; Siu, SW; Tam, PC, 2002) |
| "The effects of melatonin on prostate cancer cell proliferation and their association with mt1 receptor expression were investigated in athymic nude mice xenograft models of LNCaP and PC-3 cells." | 1.31 | Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. ( Fong, SW; Shiu, SY; Siu, SW; Xi, SC, 2001) |
| "Melatonin did not suppress and even slightly enhanced the capacity of AR binding to the ARE in the PC3-AR as well as in LNCaP cells." | 1.31 | Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells. ( Lupowitz, Z; Rimler, A; Zisapel, N, 2002) |
| "Melatonin is a hormone primarily produced by the pineal gland at night and is suppressed by exposure to light." | 1.30 | Reduced cancer incidence among the blind. ( Ahlbom, A; Feychting, M; Osterlund, B, 1998) |
| "Conventional antiandrogen therapy for prostatic cancer generally results in the death of androgen-dependent cells, resulting in shrinkage of the tumor, followed by regrowth of the tumor as androgen-insensitive cells take over." | 1.27 | Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma. ( Amerongen, HM; Buzzell, GR; Hennes, SC; McBlain, WA; O'Brien, MG; Toma, JG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (6.90) | 18.7374 |
| 1990's | 12 (13.79) | 18.2507 |
| 2000's | 25 (28.74) | 29.6817 |
| 2010's | 32 (36.78) | 24.3611 |
| 2020's | 12 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Lamphar, H | 1 |
| Kocifaj, M | 1 |
| Limón-Romero, J | 1 |
| Paredes-Tavares, J | 1 |
| Chakameh, SD | 1 |
| Mego, M | 1 |
| Prado, NJ | 1 |
| Baez-López, YA | 1 |
| Diez, ER | 1 |
| Lozano-Lorca, M | 1 |
| Olmedo-Requena, R | 1 |
| Rodríguez-Barranco, M | 1 |
| Redondo-Sánchez, D | 1 |
| Jiménez-Pacheco, A | 1 |
| Vázquez-Alonso, F | 1 |
| Arana-Asensio, E | 1 |
| Sánchez, MJ | 1 |
| Fernández-Martínez, J | 1 |
| Acuña-Castroviejo, D | 1 |
| Jiménez-Moleón, JJ | 1 |
| Vaselkiv, JB | 1 |
| Cheng, I | 1 |
| Chowdhury-Paulino, IM | 1 |
| Gonzalez-Feliciano, AG | 1 |
| Wilkens, LR | 1 |
| Hauksdóttir, AM | 1 |
| Eiriksdottir, G | 1 |
| Le Marchand, L | 1 |
| Haiman, CA | 1 |
| Valdimarsdóttir, U | 2 |
| Mucci, LA | 3 |
| Markt, SC | 3 |
| Tai, HC | 2 |
| Wang, SW | 2 |
| Swain, S | 1 |
| Lin, LW | 3 |
| Tsai, HC | 1 |
| Liu, SC | 1 |
| Wu, HC | 1 |
| Guo, JH | 1 |
| Liu, CL | 1 |
| Lai, YW | 2 |
| Lin, TH | 3 |
| Yang, SF | 2 |
| Tang, CH | 3 |
| Samanta, S | 1 |
| Wu, J | 1 |
| Tan, X | 1 |
| Balpınar, Ö | 1 |
| Nadaroğlu, H | 1 |
| Hacımüftüoğlu, A | 1 |
| Farahani, H | 1 |
| Alaee, M | 1 |
| Amri, J | 1 |
| Baghinia, MR | 1 |
| Rafiee, M | 1 |
| Chang, AC | 2 |
| Chen, PC | 2 |
| Chen, YH | 1 |
| Wang, PC | 1 |
| Chen, SS | 1 |
| Liu, PI | 1 |
| Lai, JL | 1 |
| Tsai, CH | 1 |
| Jiang, YJ | 1 |
| Huang, WC | 1 |
| Shen, D | 1 |
| Ju, L | 1 |
| Zhou, F | 1 |
| Yu, M | 1 |
| Ma, H | 1 |
| Zhang, Y | 1 |
| Liu, T | 1 |
| Xiao, Y | 1 |
| Wang, X | 1 |
| Qian, K | 1 |
| Bazzi, LA | 1 |
| Sigurdardottir, LG | 2 |
| Sigurdsson, S | 1 |
| Torfadottir, J | 1 |
| Aspelund, T | 2 |
| Czeisler, CA | 2 |
| Lockley, SW | 2 |
| Jonsson, E | 1 |
| Launer, L | 2 |
| Harris, T | 2 |
| Gudnason, V | 2 |
| Wendeu-Foyet, MG | 1 |
| Menegaux, F | 1 |
| Rodriguez-Garcia, A | 4 |
| Hevia, D | 7 |
| Mayo, JC | 8 |
| Gonzalez-Menendez, P | 3 |
| Coppo, L | 1 |
| Lu, J | 1 |
| Holmgren, A | 1 |
| Sainz, RM | 8 |
| Terraneo, L | 2 |
| Bianciardi, P | 2 |
| Virgili, E | 2 |
| Finati, E | 2 |
| Samaja, M | 2 |
| Paroni, R | 2 |
| Gobbo, MG | 1 |
| Tamarindo, GH | 1 |
| Ribeiro, DL | 1 |
| de Campos, SGP | 1 |
| Taboga, SR | 1 |
| Góes, RM | 1 |
| Calastretti, A | 1 |
| Gatti, G | 1 |
| Lucini, V | 1 |
| Dugnani, S | 1 |
| Canti, G | 1 |
| Scaglione, F | 1 |
| Bevilacqua, A | 1 |
| de Almeida Chuffa, LG | 1 |
| Seiva, FRF | 1 |
| Cucielo, MS | 1 |
| Silveira, HS | 1 |
| Reiter, RJ | 9 |
| Lupi, LA | 1 |
| Di Bella, G | 1 |
| Mascia, F | 1 |
| Colori, B | 1 |
| Bonomini, F | 1 |
| Favero, G | 1 |
| Fraschini, F | 1 |
| Rezzani, R | 1 |
| deHaro, D | 1 |
| Kines, KJ | 1 |
| Sokolowski, M | 1 |
| Dauchy, RT | 3 |
| Streva, VA | 1 |
| Hill, SM | 3 |
| Hanifin, JP | 3 |
| Brainard, GC | 3 |
| Blask, DE | 3 |
| Belancio, VP | 2 |
| Rider, JR | 1 |
| Haneuse, S | 1 |
| Fall, K | 1 |
| Schernhammer, ES | 1 |
| Tamimi, RM | 1 |
| Flynn-Evans, E | 1 |
| Batista, JL | 1 |
| Stampfer, MJ | 1 |
| Valdimarsdottir, UA | 1 |
| Erren, TC | 4 |
| Slanger, TE | 1 |
| Groß, JV | 1 |
| Quiros-González, I | 3 |
| Miar, A | 1 |
| Tan, DX | 4 |
| Papantoniou, K | 1 |
| Pozo, OJ | 1 |
| Espinosa, A | 1 |
| Marcos, J | 1 |
| Castaño-Vinyals, G | 1 |
| Basagaña, X | 1 |
| Juanola Pagès, E | 1 |
| Mirabent, J | 1 |
| Martín, J | 1 |
| Such Faro, P | 1 |
| Gascó Aparici, A | 1 |
| Middleton, B | 1 |
| Skene, DJ | 1 |
| Kogevinas, M | 1 |
| Roswall, N | 1 |
| Eriksen, KT | 1 |
| Hjortebjerg, D | 1 |
| Jensen, SS | 1 |
| Overvad, K | 1 |
| Tjønneland, A | 1 |
| Raaschou-Nielsen, O | 1 |
| Sørensen, M | 1 |
| Smolensky, MH | 1 |
| Sackett-Lundeen, LL | 1 |
| Portaluppi, F | 1 |
| Hoffman, AE | 1 |
| Wren-Dail, MA | 1 |
| Warfield, B | 1 |
| Xiang, S | 2 |
| Yuan, L | 2 |
| Dauchy, EM | 2 |
| Smith, K | 1 |
| Tai, SY | 1 |
| Huang, SP | 1 |
| Bao, BY | 1 |
| Wu, MT | 1 |
| Cepas, V | 1 |
| Gonzalez-Pola, I | 1 |
| Kim, KY | 1 |
| Lee, E | 1 |
| Kim, YJ | 1 |
| Kim, J | 1 |
| Kniaz'kin, IV | 1 |
| Tam, CW | 4 |
| Chan, KW | 1 |
| Liu, VW | 2 |
| Pang, B | 1 |
| Yao, KM | 3 |
| Shiu, SY | 9 |
| Filippov, SV | 1 |
| Joo, SS | 1 |
| Yoo, YM | 1 |
| Park, JW | 1 |
| Hwang, MS | 1 |
| Suh, SI | 1 |
| Baek, WK | 1 |
| Girschik, J | 1 |
| Glass, D | 1 |
| Ambrosini, GL | 1 |
| Fritschi, L | 1 |
| Bilski, B | 1 |
| Costa, G | 1 |
| Haus, E | 1 |
| Stevens, R | 1 |
| Pirozhok, I | 1 |
| Meye, A | 1 |
| Hakenberg, OW | 1 |
| Fuessel, S | 1 |
| Wirth, MP | 1 |
| Quiros, I | 3 |
| Gomez-Cordoves, C | 1 |
| Jung-Hynes, B | 2 |
| Huang, W | 1 |
| Ahmad, N | 2 |
| Schmit, TL | 1 |
| Reagan-Shaw, SR | 1 |
| Siddiqui, IA | 1 |
| Mukhtar, H | 1 |
| Lamson, DW | 1 |
| Gu, YH | 1 |
| Plaza, SM | 1 |
| Brignall, MS | 1 |
| Brinton, CA | 1 |
| Sadlon, AE | 1 |
| Cho, SY | 1 |
| Lee, HJ | 2 |
| Jeong, SJ | 1 |
| Kim, HS | 1 |
| Chen, CY | 1 |
| Lee, EO | 1 |
| Kim, SH | 1 |
| Kabasakal, L | 1 |
| Sener, G | 1 |
| Balkan, J | 1 |
| Doğru-Abbasoğlu, S | 1 |
| Keyer-Uysal, M | 1 |
| Uysal, M | 1 |
| Navarro, M | 1 |
| Leung, WY | 1 |
| Mao, L | 1 |
| Slakey, LM | 1 |
| Shan, B | 1 |
| Frasch, T | 1 |
| Duplessis, TT | 1 |
| Siu, SW | 2 |
| Lau, KW | 2 |
| Tam, PC | 3 |
| Law, IC | 1 |
| Yip, AW | 1 |
| Ng, WT | 1 |
| Carlson, LE | 1 |
| Speca, M | 1 |
| Patel, KD | 1 |
| Goodey, E | 1 |
| León, J | 1 |
| Manchester, L | 1 |
| Sampson, SR | 1 |
| Lupowitz, Z | 5 |
| Braiman, L | 1 |
| Zisapel, N | 6 |
| Mo, CW | 1 |
| Schwartzbaum, J | 1 |
| Ahlbom, A | 2 |
| Feychting, M | 2 |
| Connor, TP | 1 |
| Blanco, D | 1 |
| Rodríguez, C | 2 |
| Roldan, F | 1 |
| Natarajan, M | 1 |
| Pape, HG | 1 |
| Piekarski, C | 2 |
| Massion, AO | 1 |
| Teas, J | 1 |
| Hebert, JR | 1 |
| Wertheimer, MD | 1 |
| Kabat-Zinn, J | 1 |
| Bartsch, C | 4 |
| Bartsch, H | 4 |
| Flüchter, SH | 3 |
| Mecke, D | 1 |
| Lippert, TH | 1 |
| Lissoni, P | 1 |
| Cazzaniga, M | 1 |
| Tancini, G | 1 |
| Scardino, E | 1 |
| Musci, R | 1 |
| Barni, S | 1 |
| Maffezzini, M | 1 |
| Meroni, T | 1 |
| Rocco, F | 1 |
| Conti, A | 1 |
| Maestroni, G | 1 |
| Taverna, G | 1 |
| Trinchieri, A | 1 |
| Mandressi, A | 1 |
| Del Nero, A | 1 |
| Mangiarotti, B | 1 |
| Antonelli, D | 1 |
| Chisena, S | 1 |
| Pisani, E | 1 |
| Osterlund, B | 1 |
| Coker, KH | 1 |
| Gilad, E | 1 |
| Laufer, M | 1 |
| Matzkin, H | 2 |
| Xi, SC | 2 |
| Brown, GM | 1 |
| Pang, SF | 1 |
| Marelli, MM | 1 |
| Limonta, P | 1 |
| Maggi, R | 1 |
| Motta, M | 1 |
| Moretti, RM | 1 |
| Fong, SW | 1 |
| Rimler, A | 3 |
| Culig, Z | 1 |
| Levy-Rimler, G | 1 |
| Klocker, H | 1 |
| Bartsch, G | 1 |
| Lapin, V | 1 |
| Schmidt, A | 1 |
| Ilg, S | 1 |
| Bichler, KH | 1 |
| Stevens, RG | 1 |
| Davis, S | 1 |
| Thomas, DB | 1 |
| Anderson, LE | 1 |
| Wilson, BW | 1 |
| Attanasio, A | 1 |
| Gupta, D | 1 |
| Philo, R | 1 |
| Berkowitz, AS | 1 |
| Miles, A | 1 |
| Philbrick, D | 1 |
| Buzzell, GR | 2 |
| Toma, JG | 1 |
| Amerongen, HM | 1 |
| Hennes, SC | 1 |
| O'Brien, MG | 1 |
| McBlain, WA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Open-label Study to Evaluate the Effects of a Prostate Health Formulation on Scores Attained From the International Prostate Symptom Score (I-PSS) Questionnaire Among Overall Healthy Male Participants Who Report Lower Urinary Tract Complaints[NCT02886832] | 30 participants (Anticipated) | Interventional | 2016-09-21 | Completed | |||
| Diet and Chronotype: a Randomized Controlled Trial to Evaluate the Effects of a Chronotype-adapted Diet on Weight Loss in Overweight/Obese Subjects[NCT05941871] | 150 participants (Anticipated) | Interventional | 2023-03-06 | Recruiting | |||
| Circadian Health in Patients Admitted to Intensive Care Units and Hospitalization (CHRONOHOSPI)[NCT04113876] | 975 participants (Actual) | Observational [Patient Registry] | 2019-01-01 | Completed | |||
| MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate[NCT03853902] | 30 participants (Actual) | Interventional | 2016-01-26 | Completed | |||
| Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients[NCT00390169] | Phase 3 | 300 participants (Anticipated) | Interventional | 2006-10-31 | Active, not recruiting | ||
| Mind-Body Health in Uro-Oncology: A Randomized Controlled Trial[NCT03852030] | 120 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education[NCT02871752] | 225 participants (Actual) | Interventional | 2016-08-10 | Completed | |||
| Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes[NCT04417153] | 1,000 participants (Anticipated) | Observational | 2019-09-20 | Recruiting | |||
| REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology[NCT02495376] | 151 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for melatonin and Cancer of Prostate
| Article | Year |
|---|---|
The Potential Oncostatic Effects of Melatonin against Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Proliferation; Humans; Male; Melatonin; Prostatic | 2021 |
The inhibitory effect of melatonin on human prostate cancer.
Topics: Apoptosis; Humans; Male; Melatonin; Models, Biological; Prostatic Neoplasms; Receptors, Androgen; Si | 2021 |
Circadian Disruption and Prostate Cancer Risk: An Updated Review of Epidemiological Evidences.
Topics: Carcinogenesis; Cell Proliferation; Chronobiology Disorders; Circadian Rhythm; Circadian Rhythm Sign | 2017 |
Mitochondrial functions and melatonin: a tour of the reproductive cancers.
Topics: Animals; Breast Neoplasms; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Male; M | 2019 |
The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Cyclophosphamide; Dopa | 2013 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
Could mining be protective against prostate cancer? A study and literature review.
Topics: Adult; Aged; Australia; Case-Control Studies; Humans; Male; Melatonin; Middle Aged; Mining; Occupati | 2010 |
[Shift and night work--is it a cancer risk factor?].
Topics: Breast Neoplasms; Causality; Chronobiology Disorders; Circadian Rhythm; Colorectal Neoplasms; Female | 2005 |
Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment.
Topics: Cell Proliferation; Evidence-Based Medicine; Humans; Male; Melatonin; Prostatic Neoplasms | 2007 |
Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumor growth?
Topics: Aging; Animals; Breast Neoplasms; Circadian Rhythm; Endocrine Glands; Female; Humans; Male; Melatoni | 1994 |
Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies.
Topics: Antioxidants; Breast Neoplasms; Breathing Exercises; Female; Humans; Life Change Events; Male; Medit | 1999 |
Pineal gland and malignancy.
Topics: Age Factors; Animals; Breast Neoplasms; Carcinogens; Carcinoma; Female; Gonadotropins; Humans; Lymph | 1976 |
Electric power, pineal function, and the risk of breast cancer.
Topics: Animals; Breast Neoplasms; Dietary Fats; Electricity; Electromagnetic Fields; Ethanol; Female; Ferti | 1992 |
Melatonin: perspectives in laboratory medicine and clinical research.
Topics: Brain Neoplasms; Breast Neoplasms; Humans; Male; Melanoma; Melatonin; Mood Disorders; Prostatic Neop | 1987 |
1 trial available for melatonin and Cancer of Prostate
72 other studies available for melatonin and Cancer of Prostate
| Article | Year |
|---|---|
Light pollution as a factor in breast and prostate cancer.
Topics: Humans; Male; Melatonin; Prevalence; Prostatic Neoplasms; Risk Factors | 2022 |
Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Circadian Rhythm; Humans; Male; Melatonin; Mid | 2022 |
Urinary 6-sulfatoxymelatonin Levels and Prostate Cancer Risk among Men in the Multiethnic Cohort.
Topics: Case-Control Studies; Cohort Studies; Humans; Male; Melatonin; Prostatic Neoplasms; Risk Factors | 2022 |
Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α
Topics: Cell Line, Tumor; Humans; Integrin alpha2beta1; Male; Melatonin; NF-kappa B; Prostatic Neoplasms | 2022 |
The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
Topics: Breast Neoplasms; Circadian Rhythm; Cohort Studies; Databases, Factual; Female; Humans; Male; Melato | 2022 |
Green synthesis, characterization of melatonin-like drug bioconjugated CoS quantum dots and its antiproliferative effect on different cancer cells.
Topics: Cell Line, Tumor; Humans; Male; Melatonin; Neuroblastoma; Prostatic Neoplasms; Quantum Dots | 2023 |
Serum and Saliva Concentrations of Biochemical Parameters in Men with Prostate Cancer and Benign Prostate Hyperplasia.
Topics: beta 2-Microglobulin; Biomarkers; Case-Control Studies; Creatine Kinase, BB Form; Creatinine; Down-R | 2020 |
Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Movement; Cell Survival; Down-Regulation; Humans; Male; | 2021 |
Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
Topics: Animals; Bone Marrow Cells; Bone Neoplasms; Bone Resorption; Cell Differentiation; Disease Models, A | 2021 |
Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
Topics: Aged; Aged, 80 and over; Humans; Iceland; Magnetic Resonance Imaging; Male; Melatonin; Organ Size; P | 2021 |
Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells.
Topics: Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Survival; Curcumin; Gene Expression Regulation, | 2017 |
Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer.
Topics: Administration, Cutaneous; Animals; Cell Line, Tumor; Humans; Male; Melatonin; Mice; Nanostructures; | 2017 |
Pathological lesions and global DNA methylation in rat prostate under streptozotocin-induced diabetes and melatonin supplementation.
Topics: Animals; Antioxidants; Cell Proliferation; Diabetes Complications; Diabetes Mellitus, Experimental; | 2018 |
Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Humans; Male; Melatonin; Pr | 2018 |
Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling.
Topics: Animals; Humans; Hypoxia; Male; Melatonin; Mice; Mice, Nude; Prostatic Neoplasms; Signal Transductio | 2014 |
Regulation of L1 expression and retrotransposition by melatonin and its receptor: implications for cancer risk associated with light exposure at night.
Topics: Alu Elements; Animals; Cell Line, Tumor; Cells, Cultured; Darkness; Humans; Light; Long Interspersed | 2014 |
Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.
Topics: Age Factors; Biomarkers; Down-Regulation; Humans; Iceland; Incidence; Male; Melatonin; Proportional | 2015 |
Melatonin, sleep, and prostate cancer in elderly men: study, hypothesis development, and icelandic options.
Topics: Humans; Male; Melatonin; Prostatic Neoplasms; Sleep; Sleep Wake Disorders | 2015 |
Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Glucose; Glucose Transport Proteins, Facilitative; Humans; | 2015 |
Increased and mistimed sex hormone production in night shift workers.
Topics: Adult; Androgens; Breast Neoplasms; Circadian Rhythm; Estrogens; Female; Humans; Male; Melatonin; Mi | 2015 |
Residential Exposure to Road and Railway Noise and Risk of Prostate Cancer: A Prospective Cohort Study.
Topics: Aged; Airports; Cohort Studies; Environmental Exposure; Housing; Humans; Male; Melatonin; Middle Age | 2015 |
Nocturnal light pollution and underexposure to daytime sunlight: Complementary mechanisms of circadian disruption and related diseases.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Female; Humans; Lighting; Male; Melatonin; Prostatic Ne | 2015 |
Daytime Blue Light Enhances the Nighttime Circadian Melatonin Inhibition of Human Prostate Cancer Growth.
Topics: Animals; Blood Glucose; Cell Division; Circadian Rhythm; Corticosterone; Fatty Acids; Humans; Insuli | 2015 |
Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Case-Control Studies; Humans; Hydrocortisone; Male; Mela | 2016 |
IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer.
Topics: Adenocarcinoma; Animals; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Enzyme-Link | 2017 |
The association between artificial light at night and prostate cancer in Gwangju City and South Jeolla Province of South Korea.
Topics: Circadian Rhythm; Cities; Geography; Humans; Incidence; Light; Male; Melatonin; Prostatic Neoplasms; | 2017 |
[Melatonin, aging and tumors of the prostate].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Aging; Humans; Immunohistochemistry; Male; Melatonin | 2008 |
Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance.
Topics: Analysis of Variance; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; | 2008 |
Expression of melatonin and serotonin in human prostate tumors.
Topics: Adult; Aged; Aged, 80 and over; Humans; Male; Melatonin; Middle Aged; Prostatic Neoplasms; Serotonin | 2008 |
Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer.
Topics: Analysis of Variance; Apoptosis; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP | 2009 |
Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells.
Topics: Cell Line, Tumor; Data Interpretation, Statistical; Down-Regulation; Humans; Hypoxia-Inducible Facto | 2009 |
Shift work and cancer - considerations on rationale, mechanisms, and epidemiology.
Topics: Breast Neoplasms; Chronobiology Disorders; Female; Humans; Male; Melatonin; Middle Aged; Occupationa | 2010 |
Serotonin and melatonin do not play a prominent role in the growth of prostate cancer cell lines.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationsh | 2010 |
Monitoring intracellular melatonin levels in human prostate normal and cancer cells by HPLC.
Topics: Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Flow Cytometry; Humans; | 2010 |
Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells.
Topics: Apoptosis; ARNTL Transcription Factors; Blotting, Western; Cell Line, Tumor; Circadian Rhythm; CLOCK | 2010 |
Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Immunoprec | 2011 |
The vitamin C:vitamin K3 system - enhancers and inhibitors of the anticancer effect.
Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Cell Cycle; Cholecalciferol; Curcumin; Cytotoxin | 2010 |
Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells.
Topics: Cell Hypoxia; Cell Line, Tumor; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; | 2011 |
Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Epithelial Cells; Humans; Male; Melatonin; Prostate; Prostatic | 2011 |
Melatonin and beta-glucan alone or in combination inhibit the growth of dunning prostatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antioxidants; beta-Glucans; Blotting, Western; Disease Models, Animal; Glut | 2011 |
Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cytokines; Humans; Male; Melatonin; Prostatic Neoplasms; TNF-Relat | 2013 |
Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention an
Topics: Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Humans; Male; Melatonin; N | 2013 |
Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3β.
Topics: Animals; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Circadian Rhythm; Enzyme Activation; Epit | 2012 |
Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Topics: Androgens; Animals; Cell Division; Cyclin D1; Epidermal Growth Factor; ErbB Receptors; Humans; Male; | 2002 |
Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype.
Topics: Aged; Cell Division; Humans; Iodine Radioisotopes; Ligands; Male; Melatonin; Prostatic Neoplasms; Re | 2003 |
Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.
Topics: Adjuvants, Immunologic; Carcinoma, Neuroendocrine; Cell Differentiation; Cell Division; Cell Line, T | 2005 |
Role of protein kinase Calpha in melatonin signal transduction.
Topics: Cell Line, Tumor; Cell Membrane; Cytosol; Humans; Kinetics; Male; Melatonin; Prostatic Neoplasms; Pr | 2006 |
Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention.
Topics: Cell Line, Tumor; Cell Proliferation; Growth Inhibitors; Humans; Male; Melatonin; Prostatic Neoplasm | 2007 |
Cohort study of cancer risk among male and female shift workers.
Topics: Adolescent; Adult; Breast Neoplasms; Cohort Studies; Female; Humans; Male; Melatonin; Middle Aged; N | 2007 |
Melatonin as an adjuvant to therapeutic prostate cancer vaccines.
Topics: Adjuvants, Immunologic; Antioxidants; Cancer Vaccines; Humans; Male; Melatonin; Prostatic Neoplasms | 2008 |
Melatonin uptake in prostate cancer cells: intracellular transport versus simple passive diffusion.
Topics: Analysis of Variance; Biological Transport, Active; Blotting, Western; Calcium; Cell Fractionation; | 2008 |
Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro.
Topics: Analysis of Variance; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependen | 2008 |
Not all shifts are equal: it's time for comprehensive exposure metrics in chronodisruption research.
Topics: Data Interpretation, Statistical; Endometrial Neoplasms; Female; Humans; Male; Melatonin; Prospectiv | 2008 |
Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data.
Topics: Adult; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Male; Melatonin; Middle Aged; Phil | 1995 |
"The enzymatic basis for the rat liver 6-hydroxymelatonin sulfotransferase activity".
Topics: Breast Neoplasms; Humans; Male; Melatonin; Prostatic Neoplasms; Sulfotransferases | 1996 |
Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 1997 |
Variation in nocturnal urinary excretion of melatonin in a group of patients older than 55 years suffering from urogenital tract disorders.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Circadian Rhythm; Fema | 1997 |
Reduced cancer incidence among the blind.
Topics: Aged; Blindness; Breast Neoplasms; Cohort Studies; Female; Humans; Incidence; Male; Melatonin; Middl | 1998 |
Hormonal interactions in human prostate tumor LNCaP cells.
Topics: Androgens; Cell Division; Cell Survival; Drug Interactions; Estradiol; Humans; Male; Melatonin; Neop | 1999 |
Melatonin receptors in PC3 human prostate tumor cells.
Topics: Binding Sites; Cell Count; Cell Survival; Cholera Toxin; Cyclic AMP; Cyclic AMP-Dependent Protein Ki | 1999 |
Does winter darkness in the Artic protect against cancer? The melatonin hypothesis revisited.
Topics: Alaska; Arctic Regions; Breast Neoplasms; Canada; Darkness; Female; Greenland; Humans; Male; Melaton | 1999 |
Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells.
Topics: Adenocarcinoma; Blotting, Western; Calcium; Cell Division; Dihydrotestosterone; Dose-Response Relati | 2000 |
Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells.
Topics: Cell Cycle; Cell Division; Gene Expression Regulation, Neoplastic; Humans; Male; Melatonin; Prostati | 2000 |
Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression.
Topics: Animals; Antibodies, Monoclonal; Antioxidants; Apoptosis; Blotting, Western; Cell Division; Cyclin A | 2001 |
Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity.
Topics: Androgen Receptor Antagonists; Blotting, Western; Cell Nucleus; Humans; Immunohistochemistry; Male; | 2001 |
Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin.
Topics: Active Transport, Cell Nucleus; Aminoquinolines; Antineoplastic Agents; Cell Nucleus; Chelating Agen | 2001 |
Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells.
Topics: Antioxidants; Cell Cycle; DNA; Electrophoresis; Flow Cytometry; Humans; Male; Melatonin; Mutation; P | 2002 |
Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations.
Topics: Adult; Aged; Circadian Rhythm; Humans; Male; Melatonin; Middle Aged; Pineal Gland; Prostatic Neoplas | 1992 |
Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones.
Topics: Aged; Circadian Rhythm; Follicle Stimulating Hormone; Growth Hormone; Humans; Luteinizing Hormone; M | 1985 |
Inhibition of Dunning tumor growth by melatonin.
Topics: Adenocarcinoma; Animals; Gonadotropin-Releasing Hormone; Male; Melatonin; Prostatic Neoplasms; Rats; | 1988 |
Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor.
Topics: Adenocarcinoma; Androgens; Animals; Body Weight; Cell Line; Drug Implants; Male; Melatonin; Olfactor | 1988 |
Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma.
Topics: Adenocarcinoma; Androgens; Animals; DNA; Genitalia, Male; Male; Melatonin; Neoplasm Transplantation; | 1987 |